Skip to content

RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis

A Prospective, Randomized,Controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02648698
Enrollment
120
Registered
2016-01-07
Start date
2016-01-10
Completion date
2018-12-15
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Endometritis

Keywords

chronic endometritis, CD138, antibiotic, conversion rate.

Brief summary

120 cases with a diagnosis of chronic endometritis, confirmed by the presence of plasma cells in endometrial biopsy sample identified by immunohistochemical staining using CD138 antibody, have been recruited. The subjects have been randomly divided into two groups, the experimental group have been given antibiotic (Levofloxacin and Tinidazole for 14 days) treatment, the control group did not receive any antibiotic. Initially it was planned for women in the control group to take placebo,but the organization was difficult, so it was changed prior to the start of the study to an open label study. A repeat endometrial biopsy sample have been obtained 2-4 weeks after completion of the antibiotic therapy to assess the response to treatment. The conversion rate will be compared between the two groups

Detailed description

This study will be carried out at the Hysteroscopy centre of the Fuxing Hospital, Capital Medical University ,Beijing, China. A total of 120 women with chronic endometritis who fulfilled the following inclusion criteria will be recruited: 1. CD138 immunohistochemical staining of endometrial specimen showed presence of one or more plasma cells per 10HPF which confirmed chronic endometritis, according to published criteria. 2. women who were pre-menopausal. 3. no evidence of endometrial hyperplasia or malignancy or structural uterine pathology. 4. agreement to have a second endometrial biopsy \ 4 weeks after the initial endometrial biopsy. 5. written informed consent obtained Exclusion Criteria: 1. women who received steroid hormone therapy within one month of recruitment. 2. allergy or suspected allergy to the chosen antibiotic therapy. 3. women who developed any concurrent infection and received any antibiotic therapy during the period of study other than the one prescribed according to the study protocol. Power calculation: Assuming that the spontaneous CD138 conversion (from positive to negative ) rate is 25% and that the antibiotic therapy results in 60% conversion rate, the total number of subjects required in each arm of the RCT will be 37, accepting a Type I error of 0.05 and a Type II error of 0.1, and assuming a drop-out rate of 20%, 45 subjects will need to be recruited into each arm. Hence, a total of 90 subjects who fulfilled the inclusion criteria will be required. Recruitment: Women have been recruited form the day case hysteroscopy unit of the Hysteroscopy center, Fuxing Hospital, Beijing, China. The Hysteroscopy center currently carries out \ 600 day case hysteroscopy per month. In all cases, endometrial biopsy specimen will be obtained at the time of hysteroscopy for histological evaluation. Since 2013, all endometrial specimens have been routinely examined with the used of CD138 antibody to establish if there is evidence of chronic endometritis, in addition to routine histopathological examination. Previous audit showed that \ 15% of subjects had positive staining for CD138 cells.We recruited the initial 132 subjects according to the inclusion and exclusion criteria succesfully from July 2016 to December 2018. Randomization:Women who had histological confirmation of CE in an endometrial biopsy specimen and who fulfilled the inclusion criteria were randomized into the antibiotic group and control group in a 1:1 ratio using a computer-generated randomization list and sealed opaque envelopes prepared by the first author. The patients were not blinded to the antibiotic treatment. The pathologist who performed the histological evaluation was blinded to the treatment. Antibiotic therapy: Women who were randomized to the treatment group were given oral Levofloxacin and Tinidazole daily for 14 days. Women who were randomized to the control group did not receive any antibiotic. Staff Pharmacist dispense medication. Consent: written informed consent will be obtained Repeat endometrial biopsy & histological evaluation: The repeat endometrial biopsy will be performed after completion of the the antibiotic therapy. Immunohistochemical study using CD138 antibody will be performed.

Interventions

DRUGAntibiotics

Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group

Sponsors

Fu Xing Hospital, Capital Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. CD138 immunohistochemical staining of endometrial specimen showed presence of one or more plasma cells per 10HPF which confirmed chronic endometritis, according to published criteria. 2. women who were pre-menopausal. 3. no evidence of endometrial hyperplasia or malignancy or structural uterine pathology. 4. agreement to have a second endometrial biopsy \ 4 weeks after the initial endometrial biopsy. 5. written informed consent obtained

Exclusion criteria

1. women who received steroid hormone therapy within one month of recruitment. 2. allergy or suspected allergy to the chosen antibiotic therapy. 3. women who developed any concurrent infection and received any antibiotic therapy during the period of study other than the one prescribed according to the study protocol.

Design outcomes

Primary

MeasureTime frameDescription
The Conversion Rate of CE (From Positive to Negative)1-6 monthsSubjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination \ 4 weeks after recruitment in the follicular phase of the following menstrual cycle. The biopsies were graded as negative for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and positive when there was one or more plasma cell identified per 10 HPFs. To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group),

Countries

China

Participant flow

Pre-assignment details

A total of 120 subjects were assessed for eligibility. All of the 120 subjects were enrolled and randomized into the antibiotic group and the control group on a 1:1 ratio.

Participants by arm

ArmCount
Antibiotic Group
This group received antibiotic therapy Antibiotics: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
60
Control Group
This group did not receive antibiotic therapy
60
Total120

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyProtocol Violation15

Baseline characteristics

CharacteristicTotalAntibiotic GroupControl Group
Age, Continuous31.89 years
STANDARD_DEVIATION 4.7
31.86 years
STANDARD_DEVIATION 4.7
31.93 years
STANDARD_DEVIATION 4.8
BMI22.61 kg/m^2
STANDARD_DEVIATION 3.4
22.91 kg/m^2
STANDARD_DEVIATION 3.4
22.28 kg/m^2
STANDARD_DEVIATION 3.5
Miscarriage1.75 events
STANDARD_DEVIATION 1
1.59 events
STANDARD_DEVIATION 1
1.93 events
STANDARD_DEVIATION 1
Parity2.15 events
STANDARD_DEVIATION 0.9
2.15 events
STANDARD_DEVIATION 0.9
2.15 events
STANDARD_DEVIATION 0.9
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
120 Participants60 Participants60 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
China
114 participants59 participants55 participants
Sex: Female, Male
Female
120 Participants60 Participants60 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 590 / 55
other
Total, other adverse events
0 / 590 / 55
serious
Total, serious adverse events
0 / 590 / 55

Outcome results

Primary

The Conversion Rate of CE (From Positive to Negative)

Subjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination \ 4 weeks after recruitment in the follicular phase of the following menstrual cycle. The biopsies were graded as negative for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and positive when there was one or more plasma cell identified per 10 HPFs. To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group),

Time frame: 1-6 months

ArmMeasureValue (NUMBER)
Antibiotic GroupThe Conversion Rate of CE (From Positive to Negative)89.8 Percentage of participants
Control GroupThe Conversion Rate of CE (From Positive to Negative)12.7 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026